Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00679939
First received: May 15, 2008
Last updated: April 5, 2013
Last verified: April 2013

May 15, 2008
April 5, 2013
April 2008
March 2010   (final data collection date for primary outcome measure)
  • Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 52 [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region. Change in FN BMD at Week 52 was only analyzed within the Rosiglitazone arm.
  • Adjusted Percent Change From Baseline in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) at Week 76+10 Days [ Time Frame: Baseline and Week 76+10 days ] [ Designated as safety issue: No ]
    FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Baseline at Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days [ Time Frame: Week 52+10 days and Week 76+10 days ] [ Designated as safety issue: No ]
    FN BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Bone mineral density is calculated as the mineral content of a bone divided by the area of the bone. DXA is the principal technique used for measuring BMD. Percent change from Week 52+10 days to Week 76+10 days was calculated as (BMD at Week 76+10 days minus BMD at Week 52+10 days)/BMD at Week 52+10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
Bone mineral density of the hip at 52 weeks.
Complete list of historical versions of study NCT00679939 on ClinicalTrials.gov Archive Site
  • Adjusted Percent Change From Baseline in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA at Week 52 [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Baseline at Week 52 was calculated as (BMD at Week 52 minus BMD at Baseline)/BMD at Baseline x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+10 Days to Week 76 + 10 Days [ Time Frame: Week 52 + 10 days and Week 76 + 10 days ] [ Designated as safety issue: No ]
    BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Week 52 + 10 days toat Week 76 + 10 days was calculated as (BMD at Week 76 + 10 days minus BMD at Week 52 + 10 days)/BMD at Week 52 + 10 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in Femoral Neck, Total Hip, Trochanter, and Lumbar Spine BMD Via DXA From Week 52+30 Days to Week 76 + 30 Days [ Time Frame: Week 52 + 30 days and Week 76 + 30 days ] [ Designated as safety issue: Yes ]
    BMD (measured in grams per centimeters squared [g/cm^2]) was measured by DXA. Percent change from Week 52 + 30 days to Week 76 + 30 days was calculated as (BMD at Week 76 + 30 days minus BMD at Week 52 + 30 days)/BMD at Week 52 + 30 days x 100% and was assessed by analysis of covariance (ANCOVA) with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in Bone Specific Alkaline Phosphatase (BSAP) and Procollagen Type 1 N-propeptide (P1NP) From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    BSAP and P1NP levels were measured in micrograms per liter (mcg/L) from blood samples. BSAP and P1NP are indicators of bone buildup or formation. GM, geometric mean; SE, standard error. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change From Baseline in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in Carboxyterminal Cross-linked Telopeptide of Type 1 Collagen (CTX) From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    CTX levels were measured in picograms per milliliter (pg/ml) from blood samples. CTX is an indicator of bone break down or resorption. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change From Baseline in 25-Hydroxyvitamin D (Vitamin D) at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in 25-Hydroxyvitamin D (Vitamin D) From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Vitamin D levels were measured in nanomoles per Liter (nmol/L) from blood samples. Vitamin D is required for good bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change From Baseline in Intact Parathyroid Hormone (PTH) at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Adjusted Percent Change in Intact Parathyroid Hormone (PTH) From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Intact PTH levels were measured in nanograms per Liter (ng/L) from blood samples. Intact PTH is the amount of PTH circulating in the blood and influences bone health. Percent change was based on log-transformed data and was assessed by an ANCOVA with terms for treatment, baseline value, prior therapy, and region.
  • Percent Change From Baseline in Serum Estradiol at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.
  • Percent Change in Serum Estradiol From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Serum estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Estradiol is one form of the female sex hormone estrogen and influences bone health. Percent change from baseline was based on log-transformed data.
  • Percent Change From Baseline in Total Testosterone at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.
  • Percent Change in Total Testosterone From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Total testosterone levels were measured in nanomoles per Liter (nmol/L) from blood samples. Testosterone is a male sex hormone and influences bone health; total testosterone is the entire amount circulating in blood. Percent change from baseline was based on log-transformed data.
  • Percent Change From Baseline in Free Testosterone at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
  • Percent Change in Free Testosterone From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Free testosterone levels were measured as a percentage of total testosterone from blood samples. Free testosterone is the amount of testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
  • Percent Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Week 52 and Week 76 [ Time Frame: Baseline, Week 52, and Week 76 ] [ Designated as safety issue: Yes ]
    SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
  • Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    SHBG levels were measured in nanomoles per liter (nmol/L) from blood samples. SHBG binds to estradiol and testosterone and influences the amount of estradiol or testosterone available to the body for use. Percent change from baseline was based on log-transformed data.
Bone mineral density of the hip and spine at months 4, 7, 12 and 18. Measures of bone formation and resorption at months 3, 7, 12, 16 and 18. Measures of sex hormones and clacium homeostasis at months 12 and 18. Measures of clinical safety over time.
  • Percent Change in Percentage of Free Estradiol From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Free estradiol levels were measured as a percentage of serum estrogen from blood samples. Free estradiol is the amount of estrogen available to the body for use. Percent change was based on log-transformed data.
  • Percent Change in Free Estradiol From Week 52 to Week 76 [ Time Frame: Week 52 and Week 76 ] [ Designated as safety issue: Yes ]
    Free estradiol levels were measured in picomoles per Liter (pmol/L) from blood samples. Free estrodial is the amount of estrogen available to the body for use. Change was based on log-transformed data.
Not Provided
 
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus

The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Rosiglitazone
    up to 8mg/day
    Other Name: Rosiglitazone
  • Drug: Metformin
    up to 2000mg/day
  • Active Comparator: Arm 1 Treatment A
    rosiglitazone up to 8mg/day
    Intervention: Drug: Rosiglitazone
  • Active Comparator: Arm 2 Treatment B
    metformin up to 2000mg/day
    Intervention: Drug: Metformin
Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013 Apr;98(4):1519-28. doi: 10.1210/jc.2012-4018. Epub 2013 Feb 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
226
September 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female, >55 to <80 years
  • >5 years menopausal
  • Type 2 Diabetes Mellitus (T2DM) diagnosis according to American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), Canadian Diabetes Association (CDA), World Health Organization/International Diabetes Federation (WHO/IDF)
  • Drug-naïve (HbA1c < or = 9.0%); OR Prior monotherapy, submaximal doses of metformin (< or = 1000mg Metformin), sulfonylureas (< or = 5mg Glyburide, < or = 10mg Glipizide or < or = 8mg glimepiride) or full dose Januvia (100mg) (HbA1c < or = 8.5%); OR Prior monotherapy, > submaximal doses of metformin (>1000mg) or sulfonylureas (>5mg Glyburide, >10mg Glipizide or >8mg glimepiride) (HbA1c < or = 7.0%)
  • Weighs <300 lbs (136.4 kg)
  • Two or more vertebra (L1-L4) suitable for BMD measurement by dual x-ray absorptiometry (DXA)
  • Absolute BMD value consistent with T-score >-2.5 at femoral neck, lumbar spine and total hip

Exclusion Criteria:

  • Type 1 Diabetes Mellitus (T1DM) or history of diabetic ketoacidosis (DKA)
  • Renal or hepatic disease (clinically significant)
  • Hepatocellular reaction, severe edema, or medically serious fluid event associated with thiazolidinedione (TZD)
  • Recent (<6mos) history or clinical intervention for angina or myocardial infarction or is taking nitrates
  • Any stage of heart failure, i.e. New York Heart Association (NYHA) class I-IV
  • Systolic BP >160mmHg or diastolic BP >90mmHg while on antihypertensive
  • Hypersensitivity to TZDs, biguanides
  • Prior treatment with two or more oral anti-diabetic (OAD) agents
  • Bilateral hip replacements
  • Concurrent diseases affecting bone metabolism
  • Active malabsorption syndrome
  • Serum calcium outside the central lab reference range
  • Thyroid replacement therapy, serum thyroid stimulating hormone (TSH) must be within range
  • Vitamin D deficiency
  • Previous treatment with: strontium, intravenous (IV) bisphosphonate, fluoride, hormones, calcineurin inhibitors or methotrexate
  • Chronic systemic corticosteroid [e.g. glucocorticoid, mineralocorticoid] treatment of no more than two intra-articular injections within the past year or use of oral parenteral, or long-term, high-dose inhaled corticosteroids
Female
55 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00679939
AVD111179
No
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP